Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

First Posted Date
2000-06-14
Last Posted Date
2013-03-19
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT00005908
Locations
🇺🇸

National Naval Medical Center, Bethesda, Maryland, United States

Study of Allogeneic Bone Marrow Transplantation Using Matched, Related Donors in Patients With Nonmalignant Hematologic Disorders

First Posted Date
2000-06-05
Last Posted Date
2005-06-24
Lead Sponsor
Fairview University Medical Center
Registration Number
NCT00005893
Locations
🇺🇸

Fairview University Medical Center, Minneapolis, Minnesota, United States

Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Phase 1
Completed
Conditions
First Posted Date
2000-06-05
Last Posted Date
2005-06-24
Lead Sponsor
University of Minnesota
Target Recruit Count
30
Registration Number
NCT00005898
Locations
🇺🇸

University of Minnesota Cancer Center, Minneapolis, Minnesota, United States

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Myelodysplastic Syndrome and Acute Leukemia Related to Fanconi's Anemia

First Posted Date
2000-06-05
Last Posted Date
2005-06-24
Lead Sponsor
Fairview University Medical Center
Registration Number
NCT00005892
Locations
🇺🇸

Fairview University Medical Center, Minneapolis, Minnesota, United States

Study of Allogeneic Bone Marrow Transplantation Following Cyclophosphamide and Radiotherapy in Patients With Fanconi's Anemia

Not Applicable
Completed
Conditions
First Posted Date
2000-06-05
Last Posted Date
2005-06-24
Lead Sponsor
Fairview University Medical Center
Registration Number
NCT00005891
Locations
🇺🇸

Fairview University Medical Center, Minneapolis, Minnesota, United States

Scleroderma Lung Disease

First Posted Date
2000-02-10
Last Posted Date
2015-03-27
Lead Sponsor
The University of Texas Health Science Center, Houston
Target Recruit Count
158
Registration Number
NCT00004563

Comparing Therapies for the Treatment of Severe Aplastic Anemia

First Posted Date
1999-11-04
Last Posted Date
2020-09-22
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Target Recruit Count
33
Registration Number
NCT00001626
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

First Posted Date
1999-11-04
Last Posted Date
2012-12-21
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
170
Registration Number
NCT00001832
Locations
🇺🇸

National Cancer Institute (NCI), Bethesda, Maryland, United States

Drug Therapy in Lupus Nephropathy

First Posted Date
1999-11-04
Last Posted Date
2008-04-09
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
45
Registration Number
NCT00001212
Locations
🇺🇸

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Bethesda, Maryland, United States

Treatment of Wegener's Granulomatosis With Cyclophosphamide

Phase 2
Completed
Conditions
First Posted Date
1999-11-04
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
200
Registration Number
NCT00001155
Locations
🇺🇸

National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States

© Copyright 2024. All Rights Reserved by MedPath